Clinuvel Pharmaceuticals Ltd (CUV)

19.66 +0.06 (+0.31%)
Closed AUD Disclaimer

Clinuvel Pharmaceuticals Ltd Company Profile

Equity Type
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People’s Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Contact Information
Melbourne,3000 Australia
61 3 9660 4900
61 3 9660 4909
Top Executives
Susan E. Smith 0 2019 Non-Executive Director
Brenda Mary Shanahan 0 2007 Non-Executive Director
Philippe Jacques Wolgen 58 2005 CEO, MD & Director
Karen A. Agersborg 0 2018 Non-Executive Director
Willem A. Blijdorp 69 2015 Non-Executive Chairman
Jeffrey V. Rosenfeld 0 2019 Non Executive Director
John Andrew Likierman 79 2022 Non-Executive Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.